S. Catalini - Academia.edu (original) (raw)

Papers by S. Catalini

Research paper thumbnail of Malignant pancreatic apudomas

Journal of Steroid Biochemistry, 1987

Research paper thumbnail of Cystic tumors of the pancreas. Problems in differential diagnosis

International University Press - Roma, 1991

Research paper thumbnail of Role of resectional surgery for pancreatic cancer

Harwood Academic Publishers Reading (UK), 1990

Research paper thumbnail of CA 19-9: Postoperative prognostic index in pancreatic cancer

Harwood Academic Publishers Reading (UK), 1990

Research paper thumbnail of Digestive function after pylorus preserving pancreatoduodenectomy (PPPD)

International University Press - Roma, 1991

Research paper thumbnail of Treatment of advanced pancreatic cancer with LH-RH analogue

Research paper thumbnail of Survival and patterns of failure after resection for pancreatic cancer

Research paper thumbnail of CA 19-9 nel follow-up postoperatorio del carcinoma pancreatico

Research paper thumbnail of Diagnosi differenziale dei tumori cistici del pancreas

Research paper thumbnail of Androgen metabolism and pancreatic cancer

Research paper thumbnail of La nostra esperienza nel trattamento chirurgico dell'adenocarcinoma del pancreas

... al 2001 presso la 1° e 2° Clinica Orto-pedica dell'Università di Pisa sono state trattat... more ... al 2001 presso la 1° e 2° Clinica Orto-pedica dell'Università di Pisa sono state trattate chirurgicamente 40 rotture sottocutanee dei flessori delle dita della mano. ... del di-to in occasione di lavoro, in 2 casi in trauma da schiacciamento, in 4 casi non si segnalava in anam-nesi un ...

Research paper thumbnail of La chirurgia radicale nei tumori della testa del pancreas e della regione periampollare

Research paper thumbnail of Pancreatico - duodenal resection. A 22 year experience

Research paper thumbnail of Complicanze da CVC.Posizionamento percutaneo de novo o cambio su guida nella gestione del paziente in NPT

Research paper thumbnail of Surgical experience with adenocarcinoma of the pancreas

Research paper thumbnail of Hormonal treatment of advanced pancreatic cancer with LH-RH analogue

European Journal of Cancer and Clinical Oncology, 1990

Somatostatin has been shown to reduce G.I. tumour growth which may be direct via receptor binding... more Somatostatin has been shown to reduce G.I. tumour growth which may be direct via receptor binding or indirect via the effect on gastrln and other growth factors. We have analysed the effect of the long acting somatostatln analogue, Sandostatin, on the basal and gasttin stimulated growth of the followlng somatostatin and gastrin receptor pc&lve tumour cell lines: AR42J, rat pancreatic; LoVo, human colon; MKN45, human gastric; MKN45G clonal variant of MKN45 with intracellular gastrin immunoreactivlty. The basal ir growth of the first 3 cell lines was unaffected by Sandostatin (3.7 x lOa and 3.7 x lo-'MM) as measured by "Selenomethionine uptake, yet the basal growth of MKN45G was modestly inhibited (8046 of untreated control). m the growth of MKN45 xenografts was unaffected by continuously administered Sandostatin (240 and 25j@Arg, 14 day osmotic mini pumps) whereas MKN45G showed inhibited growth (pcO.001, after 13 days therapy). AR42J and LoVo were stimulated mitogenical$ in by physiological gastrln concentrations (lo-" to lo' M) and in all experiments Sandostatin (3.7 x lo* and 3.7 x lO_'M) reduced this stimulated growth. In addition, a high proportion of freshly prepared primary G.I. tumour cells have been found to respond mitogenically to G17 and it was shown that S/s colorectal and 3/5 gastric tumour cells had a signiticantly reduced gastrin response when co-treated with Sandostatin. Sandostatin may play a role in endocrine therapy of G.I. tumours.

Research paper thumbnail of Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin)

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1992

Recently non-controlled clinical trials reported encouraging results using a suppressive endocrin... more Recently non-controlled clinical trials reported encouraging results using a suppressive endocrine treatment in patients with unresectable pancreatic cancer. In this study 15 patients were given an LHRH analogue every 4 weeks (goserelin 3.6 mg), while 18 patients with advanced stage pancreatic carcinoma were given only symptomatic therapy. All patients treated with goserelin had sexual hormone suppression. Follow-up included abdominal ultrasound or computed tomography scan every 3 months; Ca 19-9 assay and routine laboratory blood tests were performed every month. No partial or complete response, no performance status or Ca 19-9 level changes were found. No significant difference in survival was seen in the two groups of patients. This study suggests that goserelin is unlikely to have a major influence on the survival of patients with advanced pancreatic carcinoma and casts further doubt upon the hormone-dependence of this neoplasm.

Research paper thumbnail of CA 19-9 as a prognostic index after resection for pancreatic cancer

Journal of Surgical Oncology, 1993

Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for... more Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for pancreatic cancer. Patients with preoperative CA 19-9 levels < 200 U/ml had significantly better prognosis than those with CA 19-9 > 200 U/ml (P < 0.001). Serum tumor marker normalized in 14 patients after tumor resection, and survival in this group was significantly higher than that of patients with persistently elevated CA 19-9 (P < 0.0001). Prognosis was also influenced by absence of lymph node metastases (P < 0.02) and radicality of resection (P < 0.005). Elevation of serum CA 19-9 levels after operation well predicted tumor recurrence from 1-10 months before clinical and radiological evidence. CA 19-9 determination is useful as a prognostic index after resection for pancreatic carcinoma and as a surveillance test in monitoring the efficacy of treatment.

Research paper thumbnail of Evaluation of surgical risk in palliation and resection of pancreatic cancer. Perspective study and tables to calculate the risk

International journal of pancreatology : official journal of the International Association of Pancreatology, 1992

High morbidity and mortality rates are reported for bypass and resective surgery of pancreatic ca... more High morbidity and mortality rates are reported for bypass and resective surgery of pancreatic cancer. In a retrospective study we correctly predicted the postoperative course in 88% of the patients who underwent bypass surgery and 83% of those who had a resection for pancreatic cancer. Before starting with clinical application of this scoring system, we undertook a prospective study to confirm its predictive value. Sixty-seven consecutive patients with pancreatic cancer were included: 42 patients underwent bypass surgery and 25 pancreatic resections. The operative mortality was 14% for palliative surgery and 0% for resective surgery. Surgical team and nurses were totally unaware of the predicted risk. The preoperative forecast proved to be correct in 81% of bypass surgery and in 88% of resective surgery, although surgical mortality had decreased from 21 to 14% for bypass surgery and from 17 to 0% for resective surgery. Tables are included to calculate the surgical risk for each of ...

Research paper thumbnail of Malignant pancreatic apudomas

Journal of Steroid Biochemistry, 1987

Research paper thumbnail of Cystic tumors of the pancreas. Problems in differential diagnosis

International University Press - Roma, 1991

Research paper thumbnail of Role of resectional surgery for pancreatic cancer

Harwood Academic Publishers Reading (UK), 1990

Research paper thumbnail of CA 19-9: Postoperative prognostic index in pancreatic cancer

Harwood Academic Publishers Reading (UK), 1990

Research paper thumbnail of Digestive function after pylorus preserving pancreatoduodenectomy (PPPD)

International University Press - Roma, 1991

Research paper thumbnail of Treatment of advanced pancreatic cancer with LH-RH analogue

Research paper thumbnail of Survival and patterns of failure after resection for pancreatic cancer

Research paper thumbnail of CA 19-9 nel follow-up postoperatorio del carcinoma pancreatico

Research paper thumbnail of Diagnosi differenziale dei tumori cistici del pancreas

Research paper thumbnail of Androgen metabolism and pancreatic cancer

Research paper thumbnail of La nostra esperienza nel trattamento chirurgico dell'adenocarcinoma del pancreas

... al 2001 presso la 1° e 2° Clinica Orto-pedica dell'Università di Pisa sono state trattat... more ... al 2001 presso la 1° e 2° Clinica Orto-pedica dell'Università di Pisa sono state trattate chirurgicamente 40 rotture sottocutanee dei flessori delle dita della mano. ... del di-to in occasione di lavoro, in 2 casi in trauma da schiacciamento, in 4 casi non si segnalava in anam-nesi un ...

Research paper thumbnail of La chirurgia radicale nei tumori della testa del pancreas e della regione periampollare

Research paper thumbnail of Pancreatico - duodenal resection. A 22 year experience

Research paper thumbnail of Complicanze da CVC.Posizionamento percutaneo de novo o cambio su guida nella gestione del paziente in NPT

Research paper thumbnail of Surgical experience with adenocarcinoma of the pancreas

Research paper thumbnail of Hormonal treatment of advanced pancreatic cancer with LH-RH analogue

European Journal of Cancer and Clinical Oncology, 1990

Somatostatin has been shown to reduce G.I. tumour growth which may be direct via receptor binding... more Somatostatin has been shown to reduce G.I. tumour growth which may be direct via receptor binding or indirect via the effect on gastrln and other growth factors. We have analysed the effect of the long acting somatostatln analogue, Sandostatin, on the basal and gasttin stimulated growth of the followlng somatostatin and gastrin receptor pc&lve tumour cell lines: AR42J, rat pancreatic; LoVo, human colon; MKN45, human gastric; MKN45G clonal variant of MKN45 with intracellular gastrin immunoreactivlty. The basal ir growth of the first 3 cell lines was unaffected by Sandostatin (3.7 x lOa and 3.7 x lo-'MM) as measured by "Selenomethionine uptake, yet the basal growth of MKN45G was modestly inhibited (8046 of untreated control). m the growth of MKN45 xenografts was unaffected by continuously administered Sandostatin (240 and 25j@Arg, 14 day osmotic mini pumps) whereas MKN45G showed inhibited growth (pcO.001, after 13 days therapy). AR42J and LoVo were stimulated mitogenical$ in by physiological gastrln concentrations (lo-" to lo' M) and in all experiments Sandostatin (3.7 x lo* and 3.7 x lO_'M) reduced this stimulated growth. In addition, a high proportion of freshly prepared primary G.I. tumour cells have been found to respond mitogenically to G17 and it was shown that S/s colorectal and 3/5 gastric tumour cells had a signiticantly reduced gastrin response when co-treated with Sandostatin. Sandostatin may play a role in endocrine therapy of G.I. tumours.

Research paper thumbnail of Hormonal treatment of unresectable pancreatic cancer with LHRH analogue (goserelin)

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1992

Recently non-controlled clinical trials reported encouraging results using a suppressive endocrin... more Recently non-controlled clinical trials reported encouraging results using a suppressive endocrine treatment in patients with unresectable pancreatic cancer. In this study 15 patients were given an LHRH analogue every 4 weeks (goserelin 3.6 mg), while 18 patients with advanced stage pancreatic carcinoma were given only symptomatic therapy. All patients treated with goserelin had sexual hormone suppression. Follow-up included abdominal ultrasound or computed tomography scan every 3 months; Ca 19-9 assay and routine laboratory blood tests were performed every month. No partial or complete response, no performance status or Ca 19-9 level changes were found. No significant difference in survival was seen in the two groups of patients. This study suggests that goserelin is unlikely to have a major influence on the survival of patients with advanced pancreatic carcinoma and casts further doubt upon the hormone-dependence of this neoplasm.

Research paper thumbnail of CA 19-9 as a prognostic index after resection for pancreatic cancer

Journal of Surgical Oncology, 1993

Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for... more Serial serum CA 19-9 assays were performed in 30 consecutive patients who underwent resection for pancreatic cancer. Patients with preoperative CA 19-9 levels < 200 U/ml had significantly better prognosis than those with CA 19-9 > 200 U/ml (P < 0.001). Serum tumor marker normalized in 14 patients after tumor resection, and survival in this group was significantly higher than that of patients with persistently elevated CA 19-9 (P < 0.0001). Prognosis was also influenced by absence of lymph node metastases (P < 0.02) and radicality of resection (P < 0.005). Elevation of serum CA 19-9 levels after operation well predicted tumor recurrence from 1-10 months before clinical and radiological evidence. CA 19-9 determination is useful as a prognostic index after resection for pancreatic carcinoma and as a surveillance test in monitoring the efficacy of treatment.

Research paper thumbnail of Evaluation of surgical risk in palliation and resection of pancreatic cancer. Perspective study and tables to calculate the risk

International journal of pancreatology : official journal of the International Association of Pancreatology, 1992

High morbidity and mortality rates are reported for bypass and resective surgery of pancreatic ca... more High morbidity and mortality rates are reported for bypass and resective surgery of pancreatic cancer. In a retrospective study we correctly predicted the postoperative course in 88% of the patients who underwent bypass surgery and 83% of those who had a resection for pancreatic cancer. Before starting with clinical application of this scoring system, we undertook a prospective study to confirm its predictive value. Sixty-seven consecutive patients with pancreatic cancer were included: 42 patients underwent bypass surgery and 25 pancreatic resections. The operative mortality was 14% for palliative surgery and 0% for resective surgery. Surgical team and nurses were totally unaware of the predicted risk. The preoperative forecast proved to be correct in 81% of bypass surgery and in 88% of resective surgery, although surgical mortality had decreased from 21 to 14% for bypass surgery and from 17 to 0% for resective surgery. Tables are included to calculate the surgical risk for each of ...